Učitavanje...

Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in GI tumor cells

Sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and the present studies have determined individually how sorafenib and vorinostat contribute to CD95 activation. Sorafenib (3-6 μM) promoted a dose-dependent increase in Src Y416, ERBB1 Y845 and CD...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Park, Margaret A., Reinehr, Roland, Häussinger, Dieter, Voelkel-Johnson, Christina, Ogretmen, Besim, Yacoub, Adly, Grant, Steven, Dent, Paul
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2933415/
https://ncbi.nlm.nih.gov/pubmed/20682655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0274
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!